BST:44R2

Stock Analysis Report

Executive Summary

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Phio Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 44R2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.7%

44R2

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

n/a

44R2

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: Insufficient data to determine how 44R2 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 44R2 performed against the German Market.


Shareholder returns

44R2IndustryMarket
7 Day16.7%-4.1%-5.7%
30 Day50.4%-8.2%-5.7%
90 Dayn/a-2.0%-3.6%
1 Yearn/a4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Phio Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Phio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 44R2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 44R2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 44R2 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 44R2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 44R2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 44R2 is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Phio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-22.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 44R2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 44R2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 44R2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 44R2 is forecast to have no revenue next year.

High Growth Revenue: 44R2 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 44R2's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Phio Pharmaceuticals performed over the past 5 years?

8.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 44R2 is currently unprofitable.

Growing Profit Margin: 44R2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 44R2 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare 44R2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 44R2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 44R2 has a negative Return on Equity (-104.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Phio Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 44R2's short term assets ($9.3M) exceed its short term liabilities ($2.0M).

Long Term Liabilities: 44R2's short term assets ($9.3M) exceed its long term liabilities ($438.0K).


Debt to Equity History and Analysis

Debt Level: 44R2 is debt free.

Reducing Debt: 44R2 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 44R2 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 44R2's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 44R2 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 44R2 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 1.3% each year.


Next Steps

Dividend

What is Phio Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 44R2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 44R2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 44R2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 44R2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 44R2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average board tenure


CEO

Gerrit Dispersyn (44yo)

0.8yrs

Tenure

US$424,956

Compensation

Dr. Gerrit Dispersyn, Dr. Med. Sc, serves as a Chief Executive Officer at Phio Pharmaceuticals Corp. (formerly knowns as at RXi Pharmaceuticals Corporation) since March 1, 2019. Dr. Dispersyn has been Pres ...


CEO Compensation Analysis

Compensation vs Market: Gerrit's total compensation ($USD424.96K) is about average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Gerrit's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Geert Cauwenbergh
Director7.8yrsUS$610.44k1.87% $120.7k
Robert Bitterman
Chairman of the Board8yrsUS$52.90k0.84% $54.3k
H. Dorman
Independent Director6.8yrsUS$42.90k0.028% $1.8k
Curtis Lockshin
Independent Director6.8yrsUS$47.90k0.028% $1.8k
Peter Campochiaro
Member of Scientific Advisory Board5.5yrsno datano data
V. Young
Member of Scientific Advisory Board7.5yrsno datano data
Pamela Pavco
Member of Scientific Advisory Board2.7yrsno datano data
Rolf Kiessling
Member of Scientific Advisory Board2.9yrsno datano data
Jeannette Graf
Member of Scientific Advisory Board7.5yrsno datano data
Robert Ferrara
Director0.3yrsno data0.35% $22.3k

6.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 44R2's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 553%.


Top Shareholders

Company Information

Phio Pharmaceuticals Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Phio Pharmaceuticals Corp.
  • Ticker: 44R2
  • Exchange: BST
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.191m
  • Listing Market Cap: US$6.446m
  • Shares outstanding: 669.43k
  • Website: https://www.phiopharma.com

Number of Employees


Location

  • Phio Pharmaceuticals Corp.
  • 257 Simarano Drive
  • Suite 101
  • Marlborough
  • Massachusetts
  • 1752
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2012
44R2DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2012
44R2BST (Boerse-Stuttgart)YesCommon StockDEEURMay 2012
0N34LSE (London Stock Exchange)YesCommon StockGBUSDMay 2012

Biography

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company’s lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/15 21:45
End of Day Share Price2020/01/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.